Related references
Note: Only part of the references are listed.Establishment and proteomic characterization of patient-derived clear cell sarcoma xenografts and cell lines
Marimu Sakumoto et al.
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL (2018)
Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma
Rieko Oyama et al.
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL (2018)
Establishment and proteomic characterization of a novel synovial sarcoma cell line, NCC-SS2-C1
Rieko Oyama et al.
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL (2018)
Establishment and characterization of novel patient-derived osteosarcoma xenograft and cell line
Fusako Kito et al.
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL (2018)
Establishment and characterization of patient-derived xenograft and its cell line of primary leiomyosarcoma of bone
Rieko Oyama et al.
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL (2018)
EWS-FLI1 employs an E2F switch to drive target gene expression
Raphaela Schwentner et al.
NUCLEIC ACIDS RESEARCH (2015)
Response of refractory Ewing sarcoma to pazopanib
Thierry Alcindor
ACTA ONCOLOGICA (2015)
Clinical activity of pazopanib in metastatic extraosseous Ewing sarcoma
Steven Attia et al.
RARE TUMORS (2015)
Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line
Joseph B. Moore et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2015)
Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum
Yutaka Yamamoto et al.
INTERNATIONAL JOURNAL OF UROLOGY (2014)
The Genomic Landscape of Pediatric Ewing Sarcoma
Brian D. Crompton et al.
CANCER DISCOVERY (2014)
Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations
Franck Tirode et al.
CANCER DISCOVERY (2014)
The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation
Andrew S. Brohl et al.
PLOS GENETICS (2014)
A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893
Judy L. Felgenhauer et al.
PEDIATRIC BLOOD & CANCER (2013)
Prospects and challenges for the development of new therapies for Ewing sarcoma
Patrick J. Grohar et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Molecular Pathogenesis of Ewing Sarcoma: New Therapeutic and Transcriptional Targets
Stephen L. Lessnick et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 7 (2012)
Phase II Study of Ganitumab, a Fully Human Anti-Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors
William D. Tap et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group
Richard B. Womer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pazopanib: a promising new agent in the treatment of soft tissue sarcomas
Bernd Kasper et al.
FUTURE ONCOLOGY (2011)
Preliminary Efficacy of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma
Heribert Juergens et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular Diagnosis in Ewing Family Tumors The Rizzoli Experience-222 Consecutive Cases in Four Years
Gabriella Gamberi et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab(CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
David Olmos et al.
LANCET ONCOLOGY (2010)
Recent advances in the molecular pathogenesis of Ewing's sarcoma
E. C. Toomey et al.
ONCOGENE (2010)
Analysis of prognostic factors in ewing sarcoma family of tumors -: Review of St. Jude Children's Rresearch Hospital studies
Carlos Rodriguez-Galindo et al.
CANCER (2007)
BAY 43-9006 inhibition of oncogenic RET mutants
F Carlomagno et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3
A Prieur et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets
MS Staege et al.
CANCER RESEARCH (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Development of the proteasome inhihitor Veleade((TM)) (Bortezomib)
J Adams et al.
CANCER INVESTIGATION (2004)
Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors
ER Lawlor et al.
ONCOGENE (2002)
Assembly of microarrays for genome-wide measurement of DNA copy number.
AM Snijders et al.
NATURE GENETICS (2001)
Share Paper
